Tango Therapeutics, Inc. TNGX 深 滬
已收盤 02-06 16:00:00 美东时间
12.51
+0.560
+4.69%
華盛通- 最 高13.18
- 今 開12.47
- 成交量 250.85万股
- 最 低 12.30
- 昨 收 11.95
- 總市值 16.85亿
- 52周最高 13.46
- 市盈率 靜 --
- 換手率 1.86%
- 52周最低 1.03
- 委 比 -35.48%
- 總股本 1.35亿
- 歷史最高 18.84
- 量 比 0.94
- 振 幅 7.36%
- 歷史最低 1.03
- 每 手 1
- 風險率 3.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $18
Guggenheim analyst Michael Schmidt maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $12 to $18.
02-06 22:45
美股大行评级 | 潜在上涨空间31.6%！巴克莱上调台积电目标价至450美元；第一地平线全国银行获5家机构上调目标价
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从77美元升至88美元；摩根士丹利：维持DraftKings"超配"评级，目标价从50美元升至53美元
01-20 10:26
Piper Sandler Maintains Overweight on Tango Therapeutics, Raises Price Target to $14
Piper Sandler analyst Kelsey Goodwin maintains Tango Therapeutics (NASDAQ:TNGX) with a Overweight and raises the price target from $11 to $14.
01-17 00:23
美股牛股 | High Roller暴涨430%！联手Crypto布局预测市场；航天公司Sidus大涨逾20%
High Roller单日暴涨430%！联手Crypto布局预测市场产品；商业航天公司Sidus大涨逾20%，此前获美军SHIELD项目合同>>
01-15 16:04
Tango Therapeutics CEO Barbara Weber Steps Down, Becomes Executive Chair; Malte Peters Appointed President And CEO
Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately – BOSTON, Jan. 08,
01-08 22:08
Tango Therapeutics Adds Independent Director to Strengthen Governance
Tango Therapeutics ( ($TNGX) ) has shared an announcement. On January 2, 2026, ...
01-05 20:28
Tango Therapeutics Appoints Sung Lee to Board of Directors
Tango Therapeutics appoints Sung Lee to its Board of Directors. Lee brings over 20 years of finance leadership experience in biopharma and tech. As CFO of companies like Cytokinetics and Vir Biotechnology, Lee has a strong track record in corporate strategy and investor relations. His expertise will support Tango’s lead program, vopimetostat, advancing into registrational studies and late-stage clinical development.
01-05 12:00
2026美股生物科技板块怎么投资？杰富瑞：关注6大首选、7大潜力和5大并购目标
杰富瑞近日发布了关于 2026 年美股生物科技行业的展望报告，聚焦行业首选投资标的、被低估的潜力企业和潜在并购机会。
2025-12-25 15:40
2026美股生物科技板块怎么投资？杰富瑞：关注这6大首选股、7大潜力标的和5大并购目标
杰富瑞近日发布了关于2026年美股生物科技行业的展望报告，聚焦行业首选投资标的、被低估的潜力企业和潜在并购机会。
2025-12-24 17:33
